98704-91-7

Upstream product

• 56624-12-5 ethyl (3-pyridyl)imidate dihydrochloride 
• 66943-05-3 1,4,7,10-tetraoxa-15-azacyclopentadecane 
• 98704-77-9 Acetic acid 5-((4S,5S)-4-methoxymethyl-5-phenyl-4,5-dihydro-oxazol-2-yl)-pyridin-2-ylmethyl ester 
• 98704-76-8 5-((4S,5S)-4-Methoxymethyl-5-phenyl-4,5-dihydro-oxazol-2-yl)-2-methyl-pyridine 1-oxide 
• 98704-75-7 5-((4S,5S)-4-Methoxymethyl-5-phenyl-4,5-dihydro-oxazol-2-yl)-2-methyl-pyridine 
• 81659-59-8 5-oxazolinyl-2-methylpyridine 
• 81659-47-4 ((4S,5S)-5-Phenyl-2-pyridin-3-yl-4,5-dihydro-oxazol-4-yl)-methanol 
• 28143-91-1 (1S,2S)-2-amino-1-phenyl-1,3-diol 
• 98704-89-3 N-chloroacetyl-aza-15-crown-5 
• 98704-78-0 [5-((4S,5S)-4-Methoxymethyl-5-phenyl-4,5-dihydro-oxazol-2-yl)-pyridin-2-yl]-methanol 

Relevant academic research and scientific papers

Nicotinic Acid Lariat Ethers: Syntheses, Complexation, and Reduction

Combination of 2-(hydroxymethyl)-5-oxazolinylpyridine 16a with lariat ethers 21 and 23 generated chiral 6-methylnicotinic oxazoline lariat ethers 22 and 24, respectively.Chiral lariat ether 24b by stereoselective metal-directed addition of methylmagnesium bromide was converted to the corresponding enantiomerically enriched N-magnesio-1,4-dihydropyridine 26.Lariat 26 and the nonlariat analogue 31 both reduced α,α,α-trifluoroacetophenone in a NADH model-like reduction to give the S alcohol 32 in low enantiomeric excess.